10.6084/m9.figshare.5868087.v1
Beato-Coelho J.
Beato-Coelho
J.
Marto J.P.
Marto
J.P.
Alves J.N.
Alves
J.N.
Marques-Matos C.
Marques-Matos
C.
Calado S
Calado
S
Araújo J.
Araújo
J.
Cunha L.
Cunha
L.
Pinho J.
Pinho
J.
Azevedo E.
Azevedo
E.
Viana-Baptista M.
Viana-Baptista
M.
Sargento-Freitas J.
Sargento-Freitas
J.
Supplementary Material for: Portuguese Observational Study of Ischaemic Stroke in Patients Medicated with Non-Vitamin K Antagonist Oral Anticoagulants
Karger Publishers
2018
Ischaemic stroke
Non-vitamin K antagonists oral anticoagulants
Preadmission anticoagulation therapy
Three months modified Rankin Scale
2018-02-08 10:24:01
Dataset
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Portuguese_Observational_Study_of_Ischaemic_Stroke_in_Patients_Medicated_with_Non-Vitamin_K_Antagonist_Oral_Anticoagulants/5868087
<b><i>Introduction:</i></b> Clinical trials and subsequent meta-analyses showed advantages of non-vitamin K antagonists oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation. The impact of preadmission anticoagulation in acute ischaemic stroke (AIS) has not been established. <b><i>Objective:</i></b> To compare functional outcome of patients with AIS with preadmission NOACs vs. VKAs. <b><i>Methods:</i></b> A retrospective analysis was conducted on consecutive AIS patients under oral anticoagulation (VKAs or NOACs) admitted in 4 Portuguese hospitals within a period of 30 months. Two primary outcomes were defined and compared between VKA and NOAC groups: symptomatic intracerebral hemorrhage transformation (sICH) and modified Rankin Scale (mRS) at 3 months. <b><i>Results:</i></b> Four hundred sixty-nine patients were included, of whom 332 (70.8%) were treated with VKA and 137 (29.2%) with NOAC. Patients’ median age was 78.0 and 234 (49.9%) were male. NOAC-treated patients had a higher median CHA<sub>2</sub>DS<sub>2</sub>-VASc score than those under VKA (5.0 vs. 4.0, <i>p</i> = 0.023). The two primary outcomes showed no statistical differences between the VKAs’ group and the NOACs’ group (sICH: 5.4 vs. 5.4% [<i>p</i> = 0.911]; mRS at 3 months: 3.0 vs. 3.0 [<i>p</i> = 0.646], respectively). <b><i>Conclusion:</i></b> Preadmission anticoagulation with NOACs in AIS has a functional impact similar to that of VKAs.